Sentences with phrase «therapy products for»

The Sacred Soul Holistics brand endeavor to introduce and develop high quality complementary and alternative therapy products for both therapists and home users alike.

Pluristem Therapeutics, Inc. engages in the development of standardized cell therapy products for the treatment of life threatening diseases.

Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

It offers to the commercialization of unrelated donor - patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

We entered into an agreement with Bayer to research, develop and commercialize AAV gene therapy products for treatment of hemophilia A.

China was the first country to approve a gene therapy product for commercial use, in 2004.

So far, the Food and Drug Administration has not approved any human gene - therapy product for sale, but the day is coming.

Not exact matches

And Xenon, a Vancouver - based biotech, completed a US$ 31 - million private equity financing last April that will allow it to further develop its product pipeline, which consists of small - molecule therapies for select neurological, cardiovascular and metabolic diseases.

«The product is just phenomenally innovative, and we've been talking about gene therapy for over 20 years.

Although the FDA can't dictate prices or reject therapies over pricing concerns (they can only focus on safety and efficacy), the agency can encourage more competition through moves like this (as well as speedier approval pathways) which could spur drug makers to produce products that ultimately lower costs for patients — a goal cited by FDA Commissioner Scott Gottlieb in announcing the list.

While they await those results, Reynolds and his team stay busy by laying the foundations for InVivo's next generation of products, part of what Reynolds envisions as a suite of spine - related therapies.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Abeona Therapeutics (ABEO)- The company announced receipt of Orphan Drug Designation from the European Medicines Agency Committee for Orphan Medicinal Products for gene therapy program ABO - 202.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develTherapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The company recently won FDA approval for its MRIdian Linac system, which is a product that marries radiation therapy and magnetic resonance imaging (MRI) together.

LANSINOH: This company makes amazing products for breastfeeding including some of our favorites: Lansinoh Signature Pro Double Electric Breast Pump, Lansinoh Thera Pearl 3 - in - 1 Breast Therapy Packs, and Lansinoh HPA Lanolin.

A leader in compression therapy products, the company uses high - quality synthetic materials to keep your garments functional for longer - and with our huge selection and competitive prices, there's no better place to buy Juzo's casual and fashion - forward products than Discount Surgical Stockings!

Lansinoh is a well trusted breastfeeding brand and TheraPearl is well known for sports therapy relief products.

If you want to invest in a sturdy and dependable product for your massage therapy business, then you should check out all that the Master Massage Pro Chair has to offer.

New products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impact.

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

A new review looks at the evidence behind the effectiveness of complementary or alternative therapies - including probiotics, prebiotics, synbiotics, fiber, and herbal medicinal products - for the treatment of bowel disorders such as irritable bowel syndrome (IBS), functional constipation, and ulcerative colitis.

«Although oral estrogens are effective for managing menopause symptoms, not enough is known about the cardiovascular safety of different oral hormone therapy products relative to each other,» said first author Nicholas L. Smith, PhD.

According to the FDA, the use of testosterone therapy has increased significantly, from 1.3 million patients in 2009 to 2.3 million patients who had a prescription for testosterone products in 2013.

The article in the journal Molecular Therapy — Nucleic Acids titled «As Technologies for Nucleotide Therapeutics Mature, Products Emerge» describes the analysis of more than 60,000 research publications related to oligonucleotide therapies.

In an early benefit assessment pursuant to the «Act on the Reform of the Market for Medicinal Products» (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new active ingredient offers an added benefit over the appropriate comparator therapy.

But they also see cause for hope in new products, therapies, and research undertaken by the industry.

The Summaries of Product Characteristics specify partly different treatment regimens both for these drugs or drug combinations and for the respective comparator therapies.

Among the interesting topics covered in Pathways are: the changing role of the patient in the total health equation and the ways in which decentralized information is affecting their expectations and demands; the dearth of pipeline products among international pharmaceutical companies against a backdrop of increased research and development spending; the dynamics of emerging markets and their rising demand for therapies in chronic disease; the value of drugs and biotechnology solutions within the context of global economic realities.

This has applications in the manufacturing of new chemical products that can be used in industry, including new drugs for cancer therapy and new electronics for computers.

If CTL019 is approved, the Swiss pharmaceutical giant plans to dole it out from about 30 preapproved sites, each trained in the multi-step process of harvesting cells, handling the product, and treating patients for the feverish and often life - threatening immune response that usually accompanies CAR - T therapy.

Commenting on Tong Yuan's treatment for Parkinson's disease, Oliver Cooper, director of the Stem Cell Facility of the Neuroregeneration Institute at McLean Hospital in Belmont, Massachusetts, and a specialist in Parkinson's disease, says, «The products offered by Tong Yuan may provide anecdotal, poorly controlled, transient improvements in the patients, but Parkinson's - disease patients need long - term therapies.»

On 1 May 2002, CNPR incorporated to become MerLion Pharmaceuticals, a home - grown Singapore drug discovery company that aims to develop new drugs for human therapy from natural product leads.

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether this new drug for MS offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G - BA).

Whether it's developing new products that will be manufactured in America, or getting and using energy more sustainably, or improving health care with better therapies and better use of information technology, or providing better protection for our troops abroad and our citizens at home, innovation will be key to our success.

The rational is to use hPSCs as potent sources of cells to produce cell therapy product (CTP) for HD patient.

The PEC - Encap ™ (also known as VC - 01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.

This should also enable commercialization of medical devices, reagents, and other products required for cell therapies through the development and dissemination of innovative methods and procedures for regenerative medicine based products.

ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.

Our definition is similar to the European Medicines Agency (EMA) definition of Advanced Therapy Medicinal Product (ATMP): «Medicinal product for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATTherapy Medicinal Product (ATMP): «Medicinal product for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATProduct (ATMP): «Medicinal product for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATproduct for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATtherapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATproduct, a somatic cell therapy medicinal product or tissue engineered product» (EMA ATtherapy medicinal product or tissue engineered product» (EMA ATproduct or tissue engineered product» (EMA ATproduct» (EMA ATMP Reg.

Most recently, she has led the planning and execution of a program for a new gene therapy product candidate, from ideation through proof - of - concept study, and mapping out the development plan.

Exclusion criteria were use of modified isotretinoin products, isotretinoin therapy for conditions other than acne vulgaris, and concomitant acne therapy.

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and gene therapy products including:

This is followed by a presentation by Dr Alaina Schlinker, Fresenius Kabi, as she discusses practical approaches to addressing some of the key processing challenges for cell and gene therapy products.

All this information is necessary before preclinical safety testing and product development for an AMD therapy in humans can take place.

Four products have already qualified for the regenerative medicine advanced therapy (RMAT) designation that provides extra interactions with the agency, and sooner.

For cell therapy applications, a viable, functional cell is the desired product.

The cell processing track aims at reproducible, safe and sustainable methods applicable in manufacturing settings for cell - based products intended for cellular therapy.

Between partnerships with Pharma, grants from the California Institute for Regenerative Medicine, and other sources of cash, Lewis says that Novocell is «well positioned to ensure we are able support our cell therapy program for the foreseeable future,» and predicts that an ESC product will enter clinical trials in 2012, «if not before then.»